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Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third cause of
cancer-related deaths, worldwide. It is essential to develop an effective prognostic biomarker and determine the
mechanisms underlying HCC invasion and metastasis.
Aims: This study aimed to investigate the expression of Golgi glycoprotein73 (GP73) and Epithelial-mesenchymal transition
(EMT) molecules such as E-cadherin and Vimentin in HCC. We also evaluated the prognostic value of GP73 in HCC.
Methods: Immunohistochemistry (IHC) was used to determine the expression of GP73 and EMT molecules in 75 HCC
specimens and the corresponding paracarcinomatous liver (PCL) tissues. Spearman’s correlation test was used to analyze
the correlation of GP73 and EMT molecules. Clinicopathological features of the HCC patients were also analyzed.
Univariate survival analysis was performed by the Kaplan–Meier method and differences among the groups were
analyzed by the Log-rank test.
Results: GP73 expression in HCC was higher compared with PCL tissues (χ2= 73.60, P < 0.05). EMT molecules were also
detected in HCC and PCL tissues. GP73 was negatively correlated with E-cadherin (r= − 0.49, P < 0.05), but positively
correlated with Vimentin (r= 0.46, P< 0.05) in HCC. GP73 was correlated with the clinicopathological features including
Edmondson grade, vascular invasion and TNM stage (P < 0.05), which was also associated with overall survival (OS) (P< 0.05).
Conclusions: GP73 was negatively with E-cadherin and positively correlated with Vimentin. It might be associated with
aggressive behavior of HCC and had influence on patients’ OS. Further research is needed to determine the potential of
GP73.




Hepatocellular carcinoma (HCC) accounts for most liver
cancers worldwide, with poor prognosis [1]. The poor
prognosis is attributed to extensive regional invasion and
distant metastasis during the initial diagnosis. However,
the mechanism underlying local invasion and distant* Correspondence: wenhao@126.com
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stated.metastasis are still unclear. Therefore, the need for effect-
ive molecular markers to evaluate the prognosis of HCC
cannot be overstated.
Recently, a new biomarker Golgi glycoprotein73 (GP73)
has been investigated for its diagnostic accuracy and po-
tential clinical application in HCC. GP73 was first disco-
vered in 2000 [2]. Many reports suggest that the GP73
expression was significantly increased in HCC unlike nor-
mal human liver cells [3]. The sensitivity and specificity of
GP73 were higher than AFP, making it an ideal marker for. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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of GP73 until now have focused merely on its role in early
diagnosis. Reports investigating the role of GP73 in cli-
nical pathology and patients’ OS are rare.
Epithelial–mesenchymal transition (EMT) is a useful
prognostic marker for survival in patients. EMT has a
close relationship with tumor invasiveness and metasta-
sis. The most representative molecules are E-cadherin
and Vimentin [6-8].
Therefore, we explored the expression of GP73,
E-cadherin and Vimentin in HCC /PCL tissues. The aim
of the study was to find the relationships among GP73
and EMT molecules and to evaluate the role of GP73 in
predicting the prognosis in HCC.
Methods
Patients and tissue samples
A total of 75 samples, including HCC and PCL tissues
were obtained by surgical resection from the First AffiliatedFigure 1 Immunohistochemistry of E-cadherin, Vimentin and GP73 in
cell membrane. Note that E-cadherin showed moderate and strong stainin
(2) (×400).Vimentin was detected in the cytoplasm and interstitial cells. No
contrast, moderate and strong staining was seen in HCC (4) (×400).GP73 p
method. Note that GP73 was almost absent in normal controls (PCL) (5). B
HCC, respectively. (×400). (6).Hospital of Xinjiang Medical University (XJMU), between
2007 and 2012. Insufficient liver tissue in the biopsy speci-
men or insufficient clinical data regarding patient out-
comes, were exclusion criteria. None of the patients
received chemotherapy or radiotherapy prior to surgery.
All patients were followed-up via telephone or question-
naires. Survival was calculated from tissue diagnosis until
the patient’s death or termination of follow-up (April
2013). We obtained consent from all patients, and deter-
mined the clinic pathology including gender, age, AFP,
HBV infection, thrombosis, tumor differentiation, vascular
invasion and TNM stage. The TNM classification system
was in accordance with the American Joint Committee
on Cancer/International Union Against Cancer (AJCC/
UICC). The tumor differentiation was based on the
Edmondson grading.
The tissue specimens were resected from the HCC
patients. We obtained the consent of all patients.
Research carried out on patients was in compliance withPCL tissues and HCC tissue (400×). E-cadherin was detected in the
g in s (PCL) (1) By contrast, it was almost absent in normal control HCC
te that Vimentin was almost absent in normal controls (PCL) (3) By
rotein expression was evaluated by an En-Vision immunohistochemical
y contrast, moderate and strong staining of GP73 was identified in
Table 1 GP73, E-cadherin and Vimentin in HCC and the
PCL tissues
Expression N Positive Negative Positive rate χ2 P
GP73
HCC 75 54 21 72.00%
PCL 75 3 72 4.00% 73.60 <0.05
E-cadherin
HCC 75 18 57 24.00%
PCL 75 66 9 88.00% 62.34 <0.05
Vimentin
HCC 75 45 30 60.00%
PCL 75 9 66 12.00% 37.50 <0.05
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Reagents
Rabbit anti-human GP73 polyclonal antibody was pur-
chased from American Proteintech Group. Rabbit anti-Table 2 The correlation between GP73 and clinic
pathologic features




Male 51 39 12 76.47%
Female 24 15 9 62.50% 1.58 0.21
Age
> 60y 33 27 6 81.82%
≤ 60y 42 27 15 64.29% 2.82 0.09
HBsAg
Positive 27 6 21 77.78%
Negative 48 15 33 68.75% 0.70 0.40
AFP value
> 400 ng/ml 12 9 3 75.00%
≤ 400 ng/ml 63 45 18 71.43% 0.06 0.80
Thrombosis
Yes 30 21 9 70.00%
No 45 33 12 73.33% 0.10 0.75
Edmondson grade
I-II 15 3 12 20.00%
III-IV 60 51 9 85.00% 25.15 <0.05
Vascular invasion
Yes 36 18 18 50.00%
No 39 36 3 92.31% 16.62 <0.05
TNM stage
T 1/2 21 9 12 42.86%
T 3/4 54 45 9 83.33% 12.29 <0.05human E-cadherin polyclonal antibodies and mouse
anti-human Vimentin monoclonal antibody were pur-
chased from Booster Company. Immunohistochemistry kit
antibodies were purchased from Zhongshan Jinqiao Bio-
technology Development Corporation.
Major instruments
Microscope, microwave oven and medical clean bench
were offered by the First Affiliated Hospital of XJMU.
Immunohistochemistry (IHC)
Immunohistochemistry was performed using En-Vision
method for IHC staining. We fixed the specimens in
10% neutral formalin and used paraffin to embed them.
We obtained deparaffinized 5-μm thicksections from the
FFPE tissue blocks with xylene, followed by rehydration
using a graduated series of ethanol. We used 3% H2O2 to
block endogenous peroxides. Microwave oven was used to
block non-specific antibody binding. The sections were
incubated separately overnight at 4°C with the primary
antibodies, at a concentration of 1:50. The secondary anti-
bodies were then added to the specimens the next day.
DAB was used as the chromogen. The staining was termi-
nated with water and the specimens counterstained with
haematoxylin.
Evaluation of IHC staining results
IHC staining results were interpreted independently by
two pathologists blinded to the outcomes. An intensity
score was assigned, representing the average intensity of
positive cells (0, none; 1, weak; 2, intermediate; 3, strong).
A proportion score was assigned, which represented the
estimated proportion of positive-staining cells (0, no posi-
tive cells; 1, 0-20%; 2, 21-50%; 3, 51–80%; 4, 81–100%).
The proportion and intensity scores were multiplied with a
immunoreactivity score (IS). The IS was further divided as
follows: 0–1 (−) ; 2–4 (+) ; 5–7 (++); >8(+++). “-~+” was
regard as low level,“++ ~ +++” was defined as high level.
Statistics
The appropriate non-parametric tests were used to inves-
tigate GP73 expression and clinicpathological parameters.
Unvaried survival analysis was performed by the Kaplan–
Meier method, and differences between the groups were
analyzed by the log-rank test. Two-tailed p-values of <0.05
were considered significant. All statistical analyses were
performed using SPSS software version 17.0 (SPSS for
Windows, Chicago, IL, USA).
Results
The expression of GP73 and EMT molecules in HCC and
PCL tissues and the inter-relationships
GP73 was detected in the cytoplasm of liver cells, which is
brown. E-cadherin was detected as a membrane-linear/
Figure 2 Survival curves of HCC patients with different levels of GP73 expression. The surival curves showed that HCC patients with high
levels of GP73 expression were different from patients with low levels.
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ling was observed in cytoplasmic and interstitial cells
(Figure 1). Data showed that GP73 staining was detected
up to 72% (54/75) in HCC, but only up to 4% (3/75) in
the PCL tissues. GP73 expressed in HCC was higher com-
pared with PCL (χ2 = 73.60, P < 0.05). The expression of
E-cadherin in HCC was 24% (18/75) compared with PCL
tissues 88% (66/75). The increased expression of Vimentin
in HCC [60% (45/75)] was higher than in PCL tissues
[12% (9/75)] (Table 1).Correlation between GP73 and clinical pathology
GP73 was associated with Edmondson grade, vascular
invasion and TNM stage. ( P < 0.05). No correlation was
detected between GP73 with gender, age, HBV infection,
AFP, or thrombosis (P > 0.05) (Table 2).GP73 expression with survival in HCC patients
We divided the 75 specimens into high and low levels.
Kaplan–Meier survival analysis and Log-rank test showed
that GP73 expression was significantly associated with the
OS (Figure 2, Table 3). The median survival time of pa-
tients with high levels of GP73 was 7 months compared
with 13 months associated with low GP73.Table 3 Kaplan–Meier survival analysis and log-rank test
of GP73
GP73 N Median OS/month 95% CI χ2 P
High levels 54 7.00 6.25~7.75 28.18 <0.05
Low levels 21 13.00 9.27~16.73Discussion
HCC is the most common primary liver cancer [9]. It is
the third leading cause of cancer-related death preceded
only by lung and stomach cancers [10]. Although pa-
tients with early diagnosis have benefited from advances
in treatment, the prognosis in HCC is still disappointing
[11], largely due to the highly invasive and metastatic
potential [12]. Therefore, it is essential to find an effec-
tive biomarker for HCC prognosis and underlying me-
chanisms of invasion and metastasis.
GP73 is a 73 kDa type-II Golgi transmembrane glyco-
protein, which was originally cloned from a library derived
from patients with adult giant-cell hepatitis [2]. Research
suggested that GP73 was overexpressed in HCC [3]. Mao
et al reported in a large sample of international groups,
that the sensitivity and specificity of GP73 in HCC were
higher than AFP. It suggested that GP73 was a new type
of molecular marker in early diagnosis of HCC [4]. Our
data showed that tissue GP73 levels were higher level in
HCC compared with PCL tissues, consistent with the pre-
liminary studies.
In 1982, Garry Greenburg and Hay first proposed
EMT [13]. Accumulating evidence indicated that EMT
was a pivotal mechanism contributing to cancer invasion
and metastasis. EMT involves multiple components, such
as E-cadherin and Vimentin.
E-cadherin expression is a hallmark of EMT [14].
E-cadherin expression is associated with the establishment
of cell polarity and tissue organization. Reduced E-cadherin
expression contributes to the transition of adenoma to car-
cinoma in animal models and is inversely correlated with
tumor stage [15-17]. Vimentin is a component of type
III intermediate filaments and the archetypal mesenchy-
mal marker most commonly used to categorize EMT.
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by a loss of epithelial features and leading to upregula-
tion of mesenchymal genes [18]. Huang found that
Vimentin expression was significantly higher in the me-
tastasis group than non-metastasis group ( P ≤ 0.05) un-
like E-cadherin [19].
In the present study, IHC analysis of the expression of
E-cadherin, Vimentin and GP73 showed that GP73 and
Vimentin levels were higher in HCC compared with PCL
tissues, unlike E-cadherin. Spearman’s correlation test in-
dicated that GP73 was positively associated with Vimentin,
but negatively with E-cadherin. The results resembled the
findings of Huang et al.
Several studies have demonstrated that GP73 overex-
pression may be associated with tumor invasiveness
[1,4,5,7,20]. Sun reported that the level of GP73 was
strongly associated with tumor size, vein invasion, and
tumor differentiation, which suggested that GP73 aug-
mented tumor invasion and metastasis [20]. Our re-
search found that GP73 was significantly correlated with
the Edmondson grade, vascular invasion and TNM stage
(all P < 0.05) (Table 2). These clinicopathological features
are characteristic of tumor invasiveness and metastatic
potential. In conjunction with the relationships among
GP73 and EMT, we hypothesize that GP73 might be
associated with invasive behavior in HCC.
In this study, survival analysis showed that patients
with high level of GP73 showed poorer OS compared
with low levels. We presumed that GP73 might correlate
with patients’ prognosis, contrary to Sun et al. Notably,
Sun proved that serum GP73 has no correlation with
prognosis, but the correlation of tissue GP73 and prog-
nosis are unknown. There exist a differentiation between
serum and tissue GP73, more studies are needed to
prove the prognostic value of GP73. And the results may
be affected by the number of specimens, histological
type and pathological grading method [21], different re-
sults were permitted.
Our study limitations relate to the small sample size of
the patients’ cohort with only 75 patients. The group size
became even smaller when divided by the high level and
low level of GP73 expression. Nonetheless, multiple lo-
gistic regression analysis was applied to assess parame-
ters independently associated with GP73.
Conclusions
In summary, GP73 expression positively correlated with
EMT molecules. High level of GP73 was associated with
Edmondson grade, vascular invasion and TNM stage.
Therefore, we conclude that GP73 involved in the regu-
lation of EMT to obtain invasion on HCC and it would
be a biomarker for assessing the prognostic values. GP73
is a prognostic biomarker. However, The regulation of
GP73 and its function are controversial and have yet tobe clarified [22]. How its occurrence in the HCC still
needs to be elucidated.
Competing interests
We certify that we have participated sufficiently in the work to take public
responsibility for the appropriateness of the experimental design and
method, and the collection, analysis, and interpretation of the data. We have
reviewed the final version of the manuscript and approve it for publication.
To the best of our knowledge and belief, this manuscript has not been
published in whole or in part nor is it being considered for publication
elsewhere.
Authors’ contributions
Y-XB, QC and YY have made substantial contributions to conception and
design, and acquisition and analysis of data. RM and LX have been involved
in drafting the manuscript or revising it critically for important intellectual
content. Y-XB has given final approval of the version to be published. All
authors read and approved the final manuscript.
Acknowledgements
This work was encouraged by the members of the Tumor Department of
Hospital of Xinjiang Medical University. We thank the Pathology Department
of the First Affiliated Hospital of Xinjiang Medical University for providing us
with the specimens. We also thank the American Proteintech Group
company and Booster Company, which offered the antibody.
Received: 19 September 2013 Accepted: 15 November 2013
Published: 6 December 2013
References
1. Yang Y, Xiao L, Bao Y, et al: Diagnostic value of Golgi-73 and AFP alone or
combination in primary hepatocelluar carcinoma. Chin J Lab Med 2012,
35(11):1034–1037.
2. Kladney RD, Bulla GA, Guo L, et al: GP73, a novel Golgi-localized protein
upregulated by viral infection. Gene 2000, 249(1-2):53–65.
3. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2001,
2:533–543.
4. Mao Y, Yang H, Xu H, et al: Golgi protein 73 (GOLPH2) is a valuable serum
marker for hepatocellular carcinoma. Gut 2010, 59:1687–1693.
5. YangY XL, Bao Y: Expression profiles and differential diagnostic value
of serum Golgi protein-73 in patients with liver cirrhosis and primary
hepatic carcinoma. Chin J Hepatol 2012, 20(12):920–924.
6. Mima K, Okabe H, Ishimoto T, et al: CD44s regulates the TGF-β-mediated
mesenchymal phenotype and is associated with poor prognosis in
patients with hepatocellular carcinoma. Cancer Res 2012, 72:3414–3423.
7. Yongli S, Hongyan W, Mingyi Z, et al: Expression of the epithelial-
mesenchymal transition-related proteins and their clinical significance in
lung adenocarcinoma. Diagn Pathol 2013, 8:89.
8. Kosuke M, Hiromtsu H, et al: Epithelial-mesenchymal transition expression
profiles as a prognostic factor for disease-free survival in hepatocellular
carcinoma: clinical significance of transforming growth factor-signaling.
Oncol Lett 2013, 5:149–154.
9. Nehal AR, Nagla SA: The diagnostic value of arginase-1 immunostaining
in differentiating hepatocellular carcinoma from metastatic carcinoma
and cholangiocarcinoma as compared to HepPar-1 Radwan and Ahmed.
Diagn Pathol 2012, 7:149.
10. Waly RS, Yangde Z, Yuxiang C: Hepatocellular carcinoma: focus on
different aspects of management. Oncology 2012, 42:1673.
11. Jemal A, Bray F, Center MM, et al: Global cancer statistics. Clin 2011,
61(2):69–90.
12. Murray G, Duncan M, Arbuckle E, et al: Matrix metalloproteinases and their
inhibitors in gastric cancer. Gut 1998, 43:791–797.
13. Yang J, Mani SA, Donaher JL, et al: Twist, master regulator of
morphogenesis, plays an essential role in tumor metastasis. Cell 2004,
117(5):927–939.
14. Shen R, Xie F, Shen H, et al: Negative correlation of LIV-1 and E-cadherin
expression in hepatocellular carcinoma cells. PLoS One 2013, 8:2.
15. Shiozaki H, Oka H, Inoue M, et al: E-cadherin mediated adhesion system in
cancer cells. Cancer 1996, 77:1605–1613.
Bao et al. Diagnostic Pathology 2013, 8:197 Page 6 of 6
http://www.diagnosticpathology.org/content/8/1/19716. Bukholm IK, Nesland JM, Karesen R, et al: E-cadherin and a-, b-, and
c-catenin protein expression in relation to metastasis in human breast
carcinoma. Pathology 1998, 185:262–266.
17. Van AE, De WO, Correia AS, et al: Defective Ecadherin/catenin complexes
in human cancer. Virchows Arch 2001, 439:725–751.
18. Kokkinos MA, Wafai R, Wong MK, et al: Vimentin and epithelial-
mesenchymal transition in human breast cancer-observations in vitro
and in vivo. Cells Tissues Organs 2007, 185:191–203.
19. Qiang H, Lei L, Chen HL, et al: Expression of Smad7 in
Cholangiocarcinoma: prognostic Significance and Implications for Tumor
Metastasis. Asian Pac J Cancer Prev 2012, 13:125–129.
20. Sun Y, Yang H, Mao Y, et al: Increased Golgi protein 73 expression in
hepatocellular carcinoma tissue correlates with tumor aggression but
not survival. Hepatology 2011, 26(7):1207–1212.
21. Leong AS: Diagnostic immunohistochemistry problems and solutions.
Pathology 1992, 24:1.
22. Lorinda MW, Sheri Y, Maria MP: Decreased survival and hepatorenal
pathology in mice with C-terminally truncated GP73. Clin Exp Pathol 2009,
2:34–47.
doi:10.1186/1746-1596-8-197
Cite this article as: Bao et al.: Expression and prognostic significance of
Golgiglycoprotein73 (GP73) with Epithelial-mesenchymal transition
(EMT) related molecules in Hepatocellular Carcinoma (HCC). Diagnostic
Pathology 2013 8:197.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
